Thanks, Donald. Revenue for the fourth quarter was up 112% year-over-year and up 16% sequentially to a record $70.1 million at the lower end of our guidance band and indicative of the weak market environment, though still up more than tenfold within just 3 years. Q4 gross profit was $37 million, translating into a 52.7% gross margin, up 50 basis points year-over-year and consistent with our guidance. Operating expenses were $39.4 million, with R&D sequentially lower to $29.4 million, reflecting a pause and tapeout activity, while SG&A was down slightly quarter-over-quarter to $10 million. In turn, our Q4 operating loss narrowed to $2.4 million versus a loss of $15.1 million in the year-ago period, driven by higher revenue, improving gross margin, and operating expense leverage. Adding back $1.4 million of depreciation, our EBITDA loss was less than $1 million. With net interest expense of $200,000, our net loss was $2.6 million, and we posted a $0.01 loss per share on a base of 181.6 million shares, again, in-line with our guidance and consensus estimates. We exited the quarter with $151.7 million of cash and equivalents, down $9 million versus Q3, primarily related to increased AR and CapEx to expand our internal test capacity, partially offset by a decline in inventory. Turning to our outlook. For the first quarter of 2024, we expect indie’s revenue to be up 38% year-over-year, but down 20% sequentially, reflecting seasonality and current industry softness, with gross margin in the 52% range. In terms of operating expenses, we are planning for $34 million in R&D, driven by accelerated product development activities, and $10 million of SG&A. Below the line, we anticipate $400,000 of net interest expense and no taxes. Assuming 186 million shares outstanding, including the full 7.7 million shares related to the retirement of 27 million warrants that we closed in November, we expect an $0.08 net loss per share. From a full-year 2024 perspective, we expect revenue to be in the $275 million to $300 million range, up 29% at the midpoint. Based on our new program and design-win pipeline, we expect Q1 to represent a trough quarter, a top-line recovery in Q2, and a resumption of outsized revenue growth in Q3 and Q4, yielding a profitability baseline on an EBITDA basis in the second half of this year, ahead of our significant 2025 radar and vision ramps. On that note, I’ll turn the call back to Donald for his closing comments.